#074: S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#072: Natalizumab (Tysabri, Tyruko) for active relapsing remitting MS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#070: Teriflunomide (Aubagio) for relapsing remitting MS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#068: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif, …) for CIS, RRMS & SPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#065: Glatiramer Acetate (Copaxone) for relapsing remitting multiple sclerosis
Glatiramer Acetate belongs to the oldest immunotherapies for relapsing remitting multiple sclerosis and is used for mild or moderate courses.
#062: Dimethyl fumarate (Tecfidera) & Diroximel fumarate (Vumerity) for relapsing remitting MS
Tecfidera and Vumerity, the fumarates for mild or moderate MS kick-off the informative series about immunotherapy for multiple sclerosis.
#055: Therapeutic decisions regarding pregnancy and lactation with Prof. Celia Oreja-Guevara
For women with MS, stable disease and smart choices promote a safe pregnancy and breastfeeding, supported by advanced treatments.
#053: EBV Insights. Shedding Light on Its Impact on MS with Prof. Dr. Christian Münz
Discover Prof. Christian Münz’s research on the connection between EBV and MS, including theories, mechanisms, and potential treatments.
#052: Sequencing and Escalation in MS Treatment with Prof. Tomas Kalincik
Prof. Kalincik gives insights into the statistical results of treatment regimens and why most PwMS benefit from highly effective therapies.
#044: Shared Decision Making (SDM) for Treatment Success in MS. Interview with Prof. Christoph Heesen
Prof. C. Heesen explains what it needs to have shared decision making in MS and where there are the pros and cons, options and limitations.
